Price movement over the last 24 hours
Abeona Therapeutics Inc vs Corsair Gaming Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Corsair Gaming Inc trades at $8.87 (market cap $968.35M). The key difference: Corsair Gaming Inc is far larger — about 2.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CRSR | |
|---|---|---|
Market Cap | $373.32M | $968.35M |
Sector | Health | Technology |
52-Week High | $7.23 | $12.14 |
52-Week Low | $4.17 | $4.58 |
Enterprise Value | $228.22M | $1.04B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Corsair Gaming (CRSR) trades at $8.89, down slightly by 0.11% on the day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly results with Q1 2026 beating expectations but faces profitability challenges with a net margin of just 0.49%. Recent developments include new AI product launches and strategic partnerships, driving positive media coverage and investor optimism about future growth prospects.
The outlook remains cautiously optimistic with analyst consensus pointing to modest upside potential to the $9.00 price target. Key opportunities include expansion into AI hardware and gaming partnerships, while risks center on thin profit margins, competitive pressures, and inconsistent earnings performance. The stock offers speculative growth potential but requires careful monitoring of execution on new initiatives.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →